Immunization of teenagers with a fifth dose of reduced DTaP-IPV induces high levels of pertussis antibodies with a significant increase in opsonophagocytic activity

Clinical and Vaccine Immunology

Volumn 18, Issue 8, 2011, Pages 1269-1274

  Aase, Audun ^a   Herstad, Tove Karin ^a   Merino, Samuel ^a   Bolstad, Merete ^a   Sandbu, Synne ^a   Bakke, Hilde ^a   Aaberge, Ingeborg S ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; BOOSTRIX POLIO; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; HEMAGGLUTININ; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INFANTRIX POLIO; PERTACTIN; PERTUSSIS ANTIBODY; PERTUSSIS TOXIN; UNCLASSIFIED DRUG;

ADOLESCENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BORDETELLA PERTUSSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; NORMAL HUMAN; OPSONIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; RESPIRATORY BURST;

ADHESINS, BACTERIAL; ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; ANTITOXINS; BACTERIAL OUTER MEMBRANE PROTEINS; BORDETELLA PERTUSSIS; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; OPSONIN PROTEINS; PERTUSSIS TOXIN; PHAGOCYTOSIS; POLIOVIRUS VACCINE, INACTIVATED; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH;

EID: 79961111579     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05067-11     Document Type: Article

References (43)

1. Aase, A., et al. 2007. Opsonophagocytic activity and other serological indications of Bordetella pertussis infection in military recruits in Norway. Clin. Vaccine Immunol. 14:855-862.
2. Aase, A., and T. E. Michaelsen. 1994. Opsonophagocytic activity induced by chimeric antibodies of the four human IgG subclasses with or without help from complement. Scand. J. Immunol. 39:581-587. (Pubitemid 24217151)
3. Barenkamp, S. J., and E. Leininger. 1992. Cloning, expression, and DNA sequence analysis of genes encoding nontypeable Haemophilus influenzae high-molecular-weight surface-exposed proteins related to filamentous hemagglutinin of Bordetella pertussis. Infect. Immun. 60:1302-1313.
4. Berbers, G. A., S. C. de Greeff, and F. R. Mooi. 2009. Improving pertussis vaccination. Hum. Vaccin. 5:497-503.
5. Bisgard, K. M., et al. 2004. Infant pertussis: who was the source? Pediatr. Infect. Dis. J. 23:985-989. (Pubitemid 40824285)
6. Burns, D. L. 2003. Type IV transporters of pathogenic bacteria. Curr. Opin. Microbiol. 6:29-34. (Pubitemid 36258533)
7. Coutte, L., et al. 2003. Role of adhesin release for mucosal colonization by a bacterial pathogen. J. Exp. Med. 197:735-742. (Pubitemid 36350868)
8. de Melker, H. E., et al. 2000. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J. Clin. Microbiol. 38:800-806.
9. de Melker, H. E., F. G. A. Versteegh, J. F. P. Schellekens, P. F. M. Teunis, and M. Kretzschmar. 2006. The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J. Infect. 53:106-113. (Pubitemid 44028673)
10. Edelman, K., et al. 2007. Immunity to pertussis 5 years after booster immunization during adolescence. Clin. Infect. Dis. 44:1271-1277. (Pubitemid 46717287)
11. Fernandez, J., et al. 2000. Prevention of Haemophilus influenzae type B colonization by vaccination: correlation with serum anti-capsular IgG concentration. J. Infect. Dis. 182:1553-1556.
12. Forsyth, K. D., C.-H. Wirsing von Konig, T. Tan, J. Caro, and S. Plotkin. 2007. Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine 25:2634-2642.
13. García-Corbeira, P., R. Dal-Ré, L. Aguilar, and J. García-de-Lomas. 2000. Seroepidemiology of Bordetella pertussis infections in the Spanish population: a cross-sectional study. Vaccine 18:2173-2176.
14. Giammanco, A., et al. 2003. European Sero-Epidemiology Network: standardisation of the assay results for pertussis. Vaccine 22:112-120. (Pubitemid 37357158)
15. Giammanco, A., et al. 2003. Analogous IgG subclass response to pertussis toxin in vaccinated children, healthy or affected by whooping cough. Vaccine 21:1924-1931. (Pubitemid 36428782)
16. Gustafsson, L., L. Hessel, J. Storsaeter, and P. Olin. 2006. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics 118:978-984. (Pubitemid 46090037)
17. He, Q., and J. Mertsola. 2008. Factors contributing to pertussis resurgence. Future Microbiol. 3:329-339. (Pubitemid 352003143)
18. Heininger, U., J. D. Cherry, and K. Stehr. 2004. Serologic response and antibody-titer decay in adults with pertussis. Clin. Infect. Dis. 38:591-594. (Pubitemid 38250973)
19. Hellwig, S. M. M., M. E. Rodriguez, G. A. M. Berbers, J. G. J. V. de Winkel, and F. R. Mooi. 2003. Crucial role of antibodies to pertactin in Bordetella pertussis immunity. J. Infect. Dis. 188:738-742. (Pubitemid 37115187)
20. Hodder, S. L., et al. 2000. Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents. Clin. Infect. Dis. 31:7-14. (Pubitemid 32268930)
21. Kirimanjeswara, G. S., L. M. Agosto, M. J. Kennett, O. N. Bjornstad, and E. T. Harvill. 2005. Pertussis toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis. J. Clin. Investig. 115:3594-3601. (Pubitemid 43121848)
22. Knuf, M., et al. 2006. Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population. Vaccine 24:2043-2048. (Pubitemid 43255145)
23. Lamberti, Y., M. L. Perez Vidakovics, L. W. van der Pol, and M. E. Rodriguez. 2008. Cholesterol-rich domains are involved in Bordetella pertussis phagocytosis and intracellular survival in neutrophils. Microb. Pathog. 44:501-511.
24. Le, T., et al. 2004. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT study. J. Infect. Dis. 190:535-544. (Pubitemid 38982093)
25. Lenz, D. H., C. L. Weingart, and A. A. Weiss. 2000. Phagocytosed Bordetella pertussis fails to survive in human neutrophils. Infect. Immun. 68:956-959. (Pubitemid 30056561)
26. Littmann, M., C. Hulsse, M. Riffelmann, and C. H. Wirsing von Konig. 2008. Long-term immunogenicity of a single dose of acellular pertussis vaccine in paediatric health-care workers. Vaccine 26:2344-2349.
27. Mattoo, S., and J. D. Cherry. 2005. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin. Microbiol. Rev. 18:326-382. (Pubitemid 40548297)
28. Meade, B. D., et al. 1995. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics 96:570-575.
29. Michaelsen, T. E., P. Garred, and A. Aase. 1991. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur. J. Immunol. 21:11-16.
30. Müller, F. M., J. E. Hoppe, and C. H. Wirsing von Konig. 1997. Laboratory diagnosis of pertussis: state of the art in 1997. J. Clin. Microbiol. 35:2435-2443.
31. Naess, L. M., et al. 1999. Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine. Vaccine 17:754-764.
32. Riffelmann, M., M. Littmann, C. Hulsse, and C. H. von Konig. 2009. Antibody decay after immunisation of health-care workers with an acellular pertussis vaccine. Eur. J. Clin. Microbiol. Infect. Dis. 28:275-279.
33. Rodriguez, M. E., et al. 2001. Fc receptor-mediated immunity against Bordetella pertussis. J. Immunol. 167:6545-6551. (Pubitemid 33081590)
34. Sandbu, S., et al. 2001. Should school children receive pertussis vaccine? Tidsskr. Nor. Laegeforen. 121:1464-1468. (Pubitemid 33708424)
35. Schellekens, J., C. H. von Konig, and P. Gardner. 2005. Pertussis sources of infection and routes of transmission in the vaccination era. Pediatr. Infect. Dis. J. 24:S19-S24. (Pubitemid 40676532)
36. Stefanelli, P., R. Ippoliti, C. Fazio, and P. Mastrantonio. 2002. Role of immune sera in the in-vitro phagocytosis of Bordetella pertussis strains. Microb. Pathog. 32:135-141. (Pubitemid 34971618)
37. Stehr, K., et al. 1998. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP Vaccine, or DT vaccine. Pediatrics 101:1-11. (Pubitemid 28030315)
38. Tran Minh, N. N., et al. 1999. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents. Pediatrics 104:e70.
39. Vergara, R., et al. 2005. Reduced-antigen-content-diphtheria-tetanus- acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age. Eur. J. Pediatr. 164:377-382. (Pubitemid 40869012)
40. Weingart, C. L., W. A. Keitel, K. M. Edwards, and A. A. Weiss. 2000. Characterization of bactericidal immune responses following vaccination with acellular pertussis vaccines in adults. Infect. Immun. 68:7175-7179. (Pubitemid 32463440)
41. Weingart, C. L., P. S. Mobberley-Schuman, E. L. Hewlett, M. C. Gray, and A. A. Weiss. 2000. Neutralizing antibodies to adenylate cyclase toxin promote phagocytosis of Bordetella pertussis by human neutrophils. Infect. Immun. 68:7152-7155. (Pubitemid 32463434)
42. Wendelboe, A. M., R. A. Van, S. Salmaso, and J. A. Englund. 2005. Duration of immunity against pertussis after natural infection or vaccination. Pediatr. Infect. Dis. J. 24:S58-S61. (Pubitemid 40676539)
43. Zepp, F., et al. 2007. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. Vaccine 25:5248-5252. (Pubitemid 46977539)